Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan

Authors :: Judith C. W. Marsh
K Amarasinghe
Vikas Gupta
A Laurie
C Dalley
Inderjeet Dokal
Source :: Bone Marrow Transplantation. 40:913-914
Publication Year :: 2007
Publisher :: Springer Science and Business Media LLC, 2007.
Abstract: Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan

Subjects :: Melphalan
Transplantation
Fatal outcome
business.industry
Hematology
medicine.disease
Fludarabine
Immunology
Monoclonal
Medicine
Alemtuzumab
Alemtuzumab/fludarabine
business
Dyskeratosis congenita
medicine.drug

Full Text Access

Tools